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ABSTRACT
Human beta-defensin-1 (hBD-1) is one of a number of small cationic host-defense peptides. Besides its
well-known broad-spectrum antimicrobial function, hBD-1 has recently been identified as
a chromosome 8p tumor-suppressor gene. The role of hBD-1 in modulating the host immune response
to oncogenesis, associated with cell signaling and potential therapeutic applications, has become
increasingly appreciated over time. In this study, multiple approaches were used to illustrate hBD-1 anti-
tumor activities. Results demonstrate that hBD-1 peptide alters human epidermal growth factor receptor
2 (HER2) signal transduction and represses retroviral-mediated transgene expression in cancer cells. Loss
of orthologous murine defense-1 (mBD1) in mice enhances nickel sulfate-induced leiomyosarcoma and
causes mouse kidney cells to exhibit increased susceptibility to HPV-16 E6/7-induced neoplastic trans-
formation. Furthermore, for the first time, a novel function of the urine-derived hBD-1 peptide was
discovered to suppress bladder cancer growth and this may lead to future applications in the treatment
of malignancy.
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Introduction
Human beta-defensin-1 (hBD-1) belongs to a group of catio-
nic host-defense peptides that are well-known for their anti-
microbial activity and plays a crucial role in the innate host
defense system.1 HBD-1 was first associated with renal and
prostate cancers through global transcriptome analysis of
human tumor tissues.2 Immuno-histochemical studies con-
firmed that cancer-specific hBD-1loss was found in 90% of
the renal clear-cell carcinomas and 82% of the human prostate
cancers.2 The hBD-1 gene is located at chromosome 8p23, an
area that has been found repeatedly to undergo tumor-
associated loss of heterozygosity. Consequently, it has been
proposed as one of the “missing” chromosome 8p tumor
suppressor genes. As a tumor suppressor, over-expression of
hBD-1 was found to induce apoptosis in human renal cancer
cells (SW-156) and the prostate cancer cell lines DU-145 and
PC-3.3,4 The synthetic hBD-1 peptide was shown to inhibit
proliferation of the TSU-Pr1 human bladder cancer cells.3
HBD-1 expression in epithelial cells is altered in multiple
human cancers. In oral squamous cell cancer (OSCC), hBD-
1 mRNA expression is deficient and the cytotoxic surface
effects of hBD-1destroy tumor cells.5 OSCC patients with no
expression of hBD-1 have a greater chance of metastasis to
lymph node.6,7 The genetic variation observed in OSCC sug-
gests that the difference in the expression of defensins is
associated with carcinogenesis and can be a tumor marker
for OSCC.6 As a secreted peptide, hBD-1 is highly
concentrated at the surface of epithelial cells.8 However, in
malignant salivary gland tumors, the intracellular location of
hBD-1 peptide shifts from the cytoplasm to the nucleus; this
intracellular translocation is believed to be associated with
oncogenesis and a sign of tumor recurrence.9,10
As antimicrobial peptides, defensins make HPV and HIV
inactive directly and suppress viral replication by altering
target cells.11 To promote adaptive immune responses, defen-
sins recruit dendritic cells and T lymphocytes to the viral
invasion site; the initial response to viral infection is to
increase hBD-1 expression in epithelial cells and plasmacytoid
dendritic cells (PDCs).12 In vitro, simplex virus-1 (HSV-1)-
induction of hBD-1 mRNA and peptide expression in PDCs
occurs as early as 2 h post-HSV-1 exposure.12 In respiratory
papillomas increased hBD-1, −2, and −3 expressions were
detected in tumor tissue suggesting that hBDs target human
papillomavirus-induced epithelial lesions.13 HBD3 has been
inducing human Langerhans cell-like DCs activation, migra-
tion, and polarization.14 HBD3 also amplifies the signaling
response to the viral mimic polyI:C through MDA5/IFIH1 in
primary bone marrow or monocyte-derived macrophages
from mouse or human.15 Furthermore, hBD-1, −2 and −3-
all have anti-HIV-1 activity both in vitro and in vivo.13
A single polymorphism in the hBD-1 gene was found to be
associated with HIV-1 infection in a population of children;
hBDs secreted in the oral cavity and breast milk may be
responsible for protection from HIV-1 transmission.16
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Human β-defensins (HBDs) are produced by a wide range
of cells throughout the body and influence multiple signaling
pathways that are involved in inflammation and immunity.17
HBD-1 is constitutively expressed in respiratory, intestinal,
and urogenital tract epithelia and presents in high concentra-
tions at the cell surface, indicating that the peptide plays an
important role in epithelial host defense.8 Human epidermal
growth factor receptor 2 (HER2) coexists with hBD-1 at the
epithelial cell surface. HER2 has no known direct activating
ligand. Heterodimerization of the receptor with other family
members such as HER1 and HER3 results in autophosphor-
ylation of tyrosine residues within the cytoplasmic domain of
the receptors and initiates a variety of signaling pathways
leading to cell proliferation and tumorigenesis. HER2 over-
expression has been seen in multiple cancers such as breast,
ovary, endometrium, bladder, lung, colon, and head and
neck.18 Currently targeted therapy reagents for HER2-
positive breast cancer are man-made monoclonal antibody
and kinase inhibitors.19 Among the identified hBDs, hBD-3
was found to compete with stromal-derived factor 1 (SDF-1),
the natural ligand for CXCR4, for cellular binding and blocks
SDF-1-induced calcium flux, ERK-1/2 phosphorylation.20
HBD2 and hBD3 along with their mouse orthologous, hBD4
and 14, bind to the chemokine receptor, CCR2, expressed by
monocytes, macrophages, and neutrophils. By binding with
CCR2 hBD-2 and hBD-3 exhibit chemotactic activity for
human peripheral blood monocytes, and mouse peritoneal
exudate cells.21 HBDs play multi-functional roles in the innate
immune system and adaptive immunity. Yet the underlying
mechanisms are still not well understood. As a coexisting
neighbor with HER2, the roles of hBD-1 in receptor-
triggered events or local interactions with other molecules
are incompletely defined.
In this study, we found the tumor-suppressing effect of
hBD-1 is associated with its ability to modulate EGFR/HER2-
associated signaling pathways; hBD-1 deficiency leads to
increased carcinogenesis in mice and renders primary mouse
kidney cells more susceptible to HPV-16 E6/7-induced onco-
genic transformation. We demonstrate hBD-1 is an inhibitor
of retroviral-based gene transduction. Furthermore, hBD-
1peptide, isolated from human urine, inhibits bladder cancer
cell growth. Future applications might involve using the
patient’s own concentrated and heat activated hBD-1 peptide
as an autologous treatment for bladder cancer.
Results
hBD-1 targets HER2-mediated cell signaling
We previously reported that hBD-1 induces Caspase-
3-mediated apoptosis in SW156 human renal cancer cells,
but the same effect was not observed in other tested cell lines.3
HBD-1 anti-tumor activity could be occurring by multiple
possible mechanisms.
To define the potential interaction between hBD-1peptide
and specific cell-surface receptors, we interrogated HER2,
a member of the human epidermal growth factor receptor
family that co-exists with hBD-1 at the epithelial cell surface.
We selected TSU-Pr1, a human bladder cancer cell line, as it
expresses both detectable levels of hBD-1 and HER2. To
determine whether hBD-1 regulates HER2 expression we per-
formed a co-culture experiment. TSU-Pr1 bladder cancer cells
were co-cultured with TSU-Pr1 cells that were transiently
transfected with hBD-1gene (TSU-Pr1/hBD-1). Protein analy-
sis revealed that levels of HER2 expression were significantly
reduced in the co-cultured TUS-Pr1cells after 48 hours incu-
bation with TSU-Pr1/hBD-1 cells in hBD-1 peptide-rich med-
ium while the expressions of LacZ controls were increased to
parental levels (Figure 1A, 1B). A corresponding decrease in
phospho-AKT was also observed (Figure 1A, 1C). To further
determine the interaction between the hBD-1 peptide and
HER2 receptors, the hBD-1/HER2 protein complex was ana-
lyzed in a mixture of BT474 human breast cancer cell lysates
and purified human urine hBD-1 peptides. BT474 is known to
express a high level of HER2 protein. When a polyclonal
hBD-1 antibody was used to pull down target proteins, the
HER2 signal was detected with monoclonal HER2 antibody
(Figure 2A, 2B). Conversely, the hBD-1 protein was also
captured by a HER2 polyclonal antibody in the same protein
mixture (Figure 2C). This finding indicates that hBD-1 pep-
tide interacts directly with the HER2 receptor and plays a role
in modulating HER2 signaling.
Loss of mBD1 promotes nickel sulfate-induced
carcinogenesis in mice
To investigate the association between mBD1 deficiency and
tumor formation, we induced soft tissue sarcoma in mice by
injecting nickel sulfate, a heavy-metal environmental
carcinogen.22 We used mBD1 knockout mice.23 which were
made from 129/Ola ES cells and backcrossed to C57BL/6.
Mice genomes were verified with Southern Blot (2D). Both
C57BL/6 and l29/Ola wild-type mice were used as controls.
A dose of nickel sulfate, 1.7 mg per mouse, was injected intra-
muscularly into the left legs of mBD1-/- mice; the right legs
were injected with dilution vehicle alone. In wild-type control
groups, mice were injected under the same conditions. The
results revealed that two out of seven mBD1-/- mice developed
sarcomas 7 months post-injection, 90 days earlier than C57BL/
6/mBD1 wild-type and 210 days earlier than 129/Ola/mBD1
wild-type mice. The rest of mBD1-/- mice died of unknown
causes within the period of 30 days post-injection before visible
tumors formed. Tumors were poorly induced in mBD1 wild-
type mice; only one out of five C57BL/6 mice developed a small
tumor 10 months post-injection. In 129/Ola wild-type group,
four out of seven eventually showed tumors at 1.5-year post-
injection, 2.5 times longer than tumor development in the
mBD1 knockout mice. These results suggest that loss of the
mBD1 enhances nickel sulfate-induced carcinogenesis and
affects the tumor latency period (Figure 2G).
Loss of mBD1 modulates host anti-tumor immune
response
The effect of nickel sulfide is proportional to the amount of Ni
particles that are phagocytized by cells. Chronic inflammation
induced by nickel sulfide is a major contribution to tumor-
igenesis and progression.24 Tumor-associated macrophages
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(TAMs) are major players in cancer-related inflammation.
TAMs together with myeloid-derived suppressor cells
(MDSC) characterized by suppressing T cell function in
tumor-bearing hosts have an important impact on disease
progression.25 To understand mBD1mediated cell response
to tumor-related inflammation, the nickel sulfide induced
tumor tissue was combined and examined for cell surface
markers, growth factors, and common cytokines using tissue
oligo arrays (Supplemental Data Figure 1, 2). Selected genes
involved in MDSC recruitment, markers of M2-polarized
TAMs, and cytokines linked to macrophage subset-specific
functions were analyzed by real-time RT-PCR and Western
blot. Compared to wild-type, mBD1null tumor tissue exhib-
ited increased expression of markers of cytokine colony sti-
mulating factor 1 (CSF-1R), CD206, F4/80, CD163, S100A8,
and S100A9 in macrophages, CD80 in B cells, CD34 in stro-
mal cells, and decreased expression of CD94 in natural killer
T cell (Figure 3A). Among these upregulated factors, CSF-1R,
CD206, CD163, and F4/80 are markers to distinguish TAM
subsets that behave more aggressively in migration/penetra-
tion function, angiogenesis, and survival time.26 In the same
tumor tissue, inflammatory cytokines, such as TNF-a, IL-10,
IL-1β, IL-1ra, and vascular endothelial growth factor (VEGF),
were all enhanced in expression compared to the wild type,
indicating the cellular environment was in favor of MDSCs
recruitment, TAM-M2 phenotype differentiation, and pro-
moting tumor cells to develop metastasis.27 The wild-type
tumor, by contrast, expressed higher in STAT1and IFNγ
produced predominantly by natural killer (NK) and natural
killer T (NKT) (Figure 3B). Moreover, the tumor with null
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Figure 1. Over-Expression of hBD-1 Inhibits HER2 and AKT signals in TSU-Pr1 Cells a. The protein expression of HER2 and pAKT was analyzed in hBD-1 transfected
TSU-Pr1 cells (left) and co-cultured TSU-Pr1 cells (right) at 24, 48, 72 h. Co-culture with hBD-1 rich medium resulted in decreasing both HER2 and pAKT protein
expression after 24 h compared with LacZ transfected cells which increased in both HER2 and pAKT protein expressions after 24 h. b. & c. The intensity of HER2 and
pAKT expression levels were quantified using ImageJ. Data were normalized to GAPDH expression.
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mBD1 peptide showed higher protein levels of inducible nitric
oxide synthase (iNOS) and phosphorylated epidermal growth
factor receptor (EGFR/pEGFR) suggesting loss of mBD1
increases cell sensitivity to tyrosine kinase-mediated cellular
proliferation, survival, and angiogenesis (Figure 3C, 3D). To
further compare host response to the chronic inflammation
and tumor, immunochemical staining of CD-68 in tumor
sections was performed and positively stained cells were
counted. Induction of CD68, a member of scavenger recep-
tors, targets activated neutrophils and macrophages in an
inflammatory response. The brown cytoplasmic stained cells
were counted at four random high power fields in each sec-
tion; a total of two 5-µm paraffin tissue sections and eight
fields in each tumor were quantified. As the photos showed in
the wild-type mouse tumor, the CD68+ cells were predomi-
nantly seen and more frequently infiltrated into the neoplastic
lesions; in mBD1-/- mouse tumor, the scattered CD 68+ cells
were mostly noted at the tumor capsule area (Figure 2E, 2F).
Overall these data suggest that loss of mBD1 allows evasion of
host immune response by decreasing the number of tumor-
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Figure 2. Western analysis of immunoprecipitated HER2 and hBD-1proteins a. HER2 was immunoprecipitated using an hBD-1 antibody as described in methods. The
HER2 protein expression was analyzed when anti-hBD-1, anti-rabbit IgG (negative control), and anti-HER2 antibodies (positive control) were used to bait in the
mixture of BT474 protein lysate and urine hBD-1peptide. b. The HER2 expression in BT474 protein lysate alone when using anti-hBD-1, anti-rabbit IgG, and anti-HER2
to bait. c. HBD-1 protein expression was analyzed when the anti-HER2 (Ab1) was used to bait in the mixture of BT474 protein lysate and urine hBD-1peptide. Purified
urine hBD-1 peptide (input) was used as a positive control. Elution hBD-1peptide from binding antibodies was proceeded with 2x SDS-PAGE loading buffer
incubating at 50ºC for 10 min. The acid level in each sample was adjusted with sodium hydroxide; 4–12% NuPAGE Novex Bis-Tris Gel was used for Western blot.
d. Genotyping of mBD1 knockout mice: Southern blot was used to identify the genotypes. Radioisotope p32 labeled probe detects both 15 kb wild-type endogenous
mBD1 allele and 21kb targeted knockout allele. e. IHC staining of mBD1-/- and mBD1+ tumor tissue sections with anti-CD68. Brown Stained cells present tumor-
infiltrating macrophages, monocytes, neutrophils, basophils, and large lymphocytes (activated lymphocytes or NK cells). f. To quantify the CD68+ cells, brown stain
cells were counted in four random high power fields in each section. Total of two 5-µm tumor paraffin tissue sections and eight fields in each group were counted.
The number of brown stained cells is presented as the ±SEM per high power field. g. Nickel Sulfate induced sarcoma in mBD1-/- mice. Nickel Sulfate was
intramuscularly injected into the left leg; dilution vehicle alone was injected into the right leg of each mouse. Photo shows 7 months post-injection. The tumor was
formed in the left leg of mBD1-/- mouse. No visible tumors were observed in wild-type control mouse.
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infiltrating macrophages, neutrophils, and natural killer cells
meanwhile increasing pro-inflammatory cytokines and the
population of M2-like TAMs characterized by poor antigen-
presenting capability and tumor promotion.
Loss of mBD1 enhances E6/E7 induced cellular
transformation
To test whether the loss of mBD1 affects cellular response to
viral carcinogens, mouse kidney mBD1-/- cells were infected
with the amphotropic retrovirus LXSN16E6E7 (ATCC). As
expected, transduction of the E6/E7 oncogene efficiently
transformed mBD1 -/- cells. Protein analysis of cell lysates
at day 7 post-transduction showed an increased expression of
HER2, HRAS, and pERK (Figure 4A). In contrast, wild-type
mouse kidney cells were not transformed by the same viral
titer and became growth arrested. Eventually, all wild-type
cells died after one subculture in selection medium. To deter-
mine that the loss of mBD1 was responsible for the altered
gene expression, the mBD1 gene was re-expressed in the
transformed mBD1-/- mouse kidney cells by lipofectamine
mediated gene transfection. The expression of mBD1 mRNA
was verified using RT-PCR (Figure 4B). The protein expres-
sions of HER2, pERK, and pSP-6 were decreased while the
mBD1-/- mouse kidney cells were re-expressing mBD1
(Figure 4C). The results suggest the loss of mBD1 weakens
resistance to transformation through the activation of onco-
genic signaling pathways.
HBD-1 inhibits transgene expression via recombinant
lenti-associated vectors
Defensins, such as alpha-defensin-1, beta-defensin-2 and rhe-
sus θ−defensin-1 were previously reported to inhibit HIV-1
replication at physiological concentrations.11 Here we investi-
gated HIV-1-based Lentiviral vector system mediated hBD-1
transduction and protein expression. The vector pLenti/
6.3-Dest (Invitrogen, Grand Island, NY) constructed with
the hBD-1 coding sequence and verified hBD-1 protein
expression demonstrated via gene transfection in 293FT pack-
age cells, TSU-PR1, and SW156 cells (Figure 4D). The same
construct was used to produce recombinant virus in package
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Figure 3. Gene Expressions in Nickel sulfate induced tumors. a & b. Genes that are associated with TAM and pro-tumor inflammatory mediators were analyzed by
quantified RT-PCR compared to wild-type controls. Samples were triplicates in each group. Results represent mean ± SD of triplicates in two separate experiments.
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cells with the third generation Lentiviral packaging system,
pMDL g/p RRE + pRSV-Rev + pMD2G + pLV vectors, in
which Tat is eliminated, and the 5ʹLTR U3 enhancer is
replaced by an RSV promoter (Invitrogen, Grand Island,
NY). Additionally, the secondary generation Lentiviral packa-
ging system, PCMVR8.91 + PMD-G vectors, that contains Tat
protein (trans-activator of transcription) and is driven by
wild-type HIV 5ʹLTR U3 (Clontech, Mountain View, CA)
was tested as well. On day 4 post-co-transfection of the
packaging vectors, the viral particles were harvested from
the culture medium and used to infect to target cells, TSU-
PR1, SW156, and mouse kidney mBD1-/- cells. The level of
protein expression was then measured at day 7 by Western
blot for hBD-1 and X-gal staining for LacZ controls. The
result demonstrates that hBD-1 protein was absent in the
medium of all infected cell lines, while the LacZ control
showed robust signal (Figure 4E). Five repeated experiments
mediated by either the second or third generations of
Lentiviral packaging systems showed lack of hBD-1 protein
translation in all transduced cell lines suggesting that this
phenomenon is associated with hBD-1 interruption of viral
transgene expression and independent of Tat transactivation
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(Table 1). In mBD1-/- mouse kidney cells that have no endo-
genous mBD1 peptide, several transduced clones formed and
showed mBD1 mRNA transcription but protein translation
was undetectable (data not shown). To further determine the
role of hBD-1 in inhibition of gene transduction, the effi-
ciency of LacZ gene expression in the presence of hBD-1
peptide was evaluated in transduced cells. The level of beta-
galactosidase production in TSU-Pr1 cells that were infected
with Lenti/LacZ viral particles was measured at 24 h post
infection. Compared to the TSU-Pr1 cells that were previously
transfected with an empty vector, beta-galactosidase activity
was reduced by 40% in the cells that had over-expressed hBD-
1peptide (Figure 4F).28 These results suggest both endogenous
and exogenous hBD-1 peptides that endure in tissue culture
medium play a role in interrupting lentiviral transgene
expression.
Urinary hBD-1: a natural bladder cancer inhibitor
Over-expression of hBD-1 kills human kidney cancer cells
SW156; synthetic hBD-1 peptide inhibits bladder cancer
cells TSU-Pr1 growth.3 In this study, with sustained hBD-1
expression, cell death was observed in mouse kidney cancer
cells RAG within 3 weeks while the vector controls were
forming robust foci. The hBD-1 transfected RAG cells
appeared healthy initially and formed colonies, once cell
death was initiated, colonies were completely destroyed within
hours (Figure 5H, 5I). Human kidney produces the most
hBD-1 of any organ; the concentration of purified hBD-1
peptides in voided urine varies from 10 −100 µg/liter.8 The
effects of the variable hBD-1 levels and the influence in con-
trolling viral infection or local tumor incidences remain
unknown. To determine the role that urine-derived hBD-1
peptide plays in relation to urinary tract malignancies, we
treated bladder cancer cells TSU-Pr1 with purified urine
hBD-1 peptide at concentrations of 3.125–6.25 µg/ml
(0.8 µM −1.6 µM) q.d. in heat activated and non-heat acti-
vated forms. According to a previous study, hBD-1 plasma
concentration in healthy population was 8.85 ng/mL,
7.46–9.69, p < 0.001 measured using ELISA29 The cellular
proliferation rate and protein levels in the treated cells were
analyzed at multiple time points (Figure 5A, 5B). The heat
activated peptide inhibited cell growth at 24 and 48 h in
a dose-dependent manner (Figure 5A). Compared to BSA
controls, cells treated with the higher dose of 6.25 µg/ml
achieved up to 35% of the growth inhibition at 48 h (Figure
5A). Protein analysis indicated that HER2 epidermal growth
factor receptor was significantly downregulated at this period
of time (Figure 5B, 5C). Cell death and morphological
changes were observed in culture (Figure 5F, 5G). Non-heat
activated peptide showed a similar effect on TSU-Pr1 cells but
required a 2–3 fold longer treatment time (data not shown).
A cell viability assay was performed on TSU-Pr1 cells; the
value of LC50 measured at 48 h post-treatment was 0.364 µM
(Supplemental Date Figure 3).
Discussion
To investigate hBD-1 anti-tumor mechanisms, we compared
the effects of carcinogen-induced neoplasm in mBD1 null
animals to wild-type controls. The findings of enhanced
tumor induction by nickel sulfide in mBD1 null mice demon-
strate that mBD1 is a natural host carcinogenic barrier in vivo.
Tumor tissue analysis uncovered the details of tumor progres-
sion and macrophage-mediated host defense in the mBD1 null
tumor microenvironment. The lower number of tumor-
infiltrating macrophages and CD94+ NK cells observed in the
mBD1 null tumors support the hypothesis that hBD-1 may
function as a cytokine for antigen-presenting cells, especially
macrophages and dendritic cells to regulate their tumor infil-
tration, both directly and indirectly through the other
cytokines.30,31 Most important, the presence of mBD1peptide
is critical in regulating macrophage differentiation. Although
the detection on the basis of CD68 did not allow us to identify
the macrophage subsets of M1 or M2, three other currently
used M2 markers, CD206, CD163, F4/80, were increased in
mBD1 null tumor tissue, indicating that tumor-associated
macrophages M2 (TAMs-M2) were present, predominantly
in mBD1 null tumors.32 In tumor development, high levels of
TGF-β produced in TAMs and MDSCs favor tumor growth,
metastasis, and immune escape.33 TGF-β demonstrated to pro-
mote macrophage polarization toward an M2-like phenotype
characterized by increased expression of the anti-inflammatory
cytokine IL-10 and mannose receptor CD206 in macrophages.-
34 Our findings in mBD1 null tumors support this theory,
though with slight increases TGF-β expression. The role of
Table 1. Over-expression hBD-1 protein in cancer cells.
Name Cell Type
pcDNA3.1/hBD1
Transfection with Lipofectamin 2000 or FuGENE6
pLenti6.3/hBD1
Transfection with Lipofectamin2000
or FuGENE6
pLenti6.3/hBD1
Lentiviral transduction
PC-3 Human prostate cancer - - -
DU145 Human prostate cancer + + -
SW156 Human hypernephroma + + -
TSU-Pr1 Human bladder cancer + + -
mBD1-/- Cells mouse kidney - - -
3LL mouse lung cancer - - -
BT474 Human breast cancer - - -
Hela Human cervical cancer - - -
SKOV3 Human ovarian cancer - - -
RAG mouse kidney adenocarcinoma - + -
293FT Lentivirus packaging cells + + n/a
(+) = hBD1 protein was detectable in the cultural medium by Western blot
(-) = hBD1 protein was not detectable in the cultural medium by Western blot
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TGF-β is mainly regulated by the level of activation rather than
the amount of inactive TGF-β to be transcribed.35 Tumor with-
out hBD-1 grows faster with more severe inflammatory events,
that can trigger the activation of TGF-β in vivo and add more
factors to impair T and NK cell functions contributing to the
level of immunoparalysis.35 To evaluate whether this is TGF-β-
dependent regulation, two TGF-β negative regulators, IL-12/
IL-18, were examined as well. The expression of IL-12/IL-
12p40 was low or undetectable in both mBD1null tumor tissue
and wild-type (data not shown); the mean gene expression of
IL-18 was not significantly different between these two tested
groups (Figure 3B). This suggests that mBD1 involved TGF-β/
IL-10/IL-12/IL-18 paradigmatic regulation in the development
and differentiation of T helper cells subsets is affected dynami-
cally by more factors. In addition, the enhanced expression of
CSF1R along with increased CSF1peptides (Supplemental Data
Figure 2), VEGF, cytotoxic mediators such as TNF-α, IL-1RA,
IL-1β, IL-10, S100A8/A9, and iNOS, constitute a pro-tumor
inflammatory reaction and favor the adoption of TAMs-M2
towards carcinogenesis.36 Typically, M2-like population pre-
sents antigen less efficiently, displays little tumoricidal activity,
produces angiogenic factors, and promotes tumor
development.37 The CD68+CD206+ M2 TAMs in human lung
cancers were found to be significantly associated with p-TNM
staging, lymph node metastasis, and poor prognosis.38 Loss of
mBD1 upregulated the expression of pEGFR, VEGF, and iNOS,
suggesting this small peptide plays a role in modulating EGFR-
VEGF(R) pathways.39,40 One of the host defense mechanisms
of mBD1 could be acting as EGFR kinase inhibitor to directly
block the EGFR/HER activation on the cell surface and/or
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indirectly via inhibiting the differentiation of M2-like TAMs to
attenuate the positive feedback cycle between TAM-derived
epidermal growth factor (EGF) and tumor-derived colony-
stimulating factor (CSF)-1.25,37 Besides the classical mem-
brane-associated EGFR/HER activation, loss of mBD1 peptide
may intensify HER-family member translocation to the nucleus
where they regulate transcription via EGFR and STAT3 inter-
actions. This process tends to produce inducible nitric oxide
synthase (iNOS) which, in turn, leads to increased cellular
nitric oxide (NO) and mediates angiogenesis.41 Overall,
enhanced expression of TAM-associated factors in the
mBD1null tumors, such as GM-CSF, IL-10, TGF-β, and IL-
1β, along with increased iNOS and VEGF, contributes to
MDSCs recruitment, intensifies their immune suppressive
activities, and is associated with poor prognosis.38,42,43
In this study, increased expression of CD34 in stromal
cells, as well as high CSF-1, was observed in the mBD1null
tumors. CD34+ stromal cells, also called CD34+ dendritic
interstitial cells, are precursors of mature macrophages.44 In
the presence of high CSF-1, CD34+ cells could be promoted
to differentiate to immature DC/macrophages via generating
CD14+ antigen-presenting cells (APCs) (Supplemental Data
Figure 2).45,46 Similar to the functionally polarized M2-like
TAM, immature macrophages play a key role in promoting
tumor growth.47 To date, multiple types of CD34 over-
expressing sarcomas have been reported in the locations
where hBD-1 is normally in high concentrations, such as
alveolar soft tissue sarcoma, gastrointestinal stromal tumors,
granulocytic sarcoma, Kaposi’s sarcoma, and myofibrosar-
coma of the breast.48 Further investigation is crucial to deter-
mine whether loss of hBD-1 is associated with a high CD34
+ sarcoma formation in these locations.
Our study demonstrates that:
● Both transfected and urine-derived hBD-1 peptides inhi-
bit cancer cell proliferation as well as altering HER2
expression and phosphorylation of AKT and ERK.
● Chronic inflammation induced mBD1 null tumors to
enhance pEGFR compared to the wild-type.
● HPV-16E6E7 transduced mBD1 null mouse kidney cells
upregulate HER2, KRAS and phosphorylated ERK.
● Re-expression of mBD1 was able to successfully reduce
the expression of HER2, pERK, and pSP-6.
These data support the hypothesis that hBD-1 contributes to
cancer suppression via regulation of the HER2/EGFR path-
way. The decreased HER2 expression in TSU-Pr1 cells, while
in co-culture with hBD-1 peptide-rich medium, and the co-
immunoprecipitation of hBD-1 and HER2, suggest a direct
interaction between these two molecules.
The question remains whether hBD-1’s anti-tumor func-
tion is independent of its anti-microbial function. Our data
demonstrate that loss of mBD1 in mouse kidney cells leads to
an increased susceptibility to retrovirus LXSN16E6E7 infec-
tion, resulting in spontaneous cell transformation with
enhanced HRAS and p-ERK expression. Lentiviral vector-
carrying hBD-1 coding sequences were silenced in their pro-
tein translation following transduction and integration in
target cells. The decreased LacZ gene expression in the
presence of hBD-1 peptide suggests that the efficiency of
recombinant retrovirus infection and DNA integration may
be interrupted as well. Loss of hBD-1 altered HER2 and
p-ERK expression, suggesting that HER2 enhances the retro-
viral transduction efficiency while hBD-1 protects cells from
retrovirus-mediated transformation.
Finally, we found that heat-activated urine hBD-1 peptide
kills bladder cancer cells and slows their proliferation. Urine is
a convenient resource for large amounts of hBD-1 and could
contribute to a new treatment for bladder cancer using the
patient’s own concentrated and heat-activated hBD-1 peptide
as an autologous local drug for intra-vesical installation. This
unique and novel approach could be beneficial in avoiding
deleterious side effects of other intra-vesical therapies, includ-
ing toxic and immune responses while reducing cost.
Methods and materials
Cell culture
Human prostate cancer cell lines DU145 and PC-3, human
kidney cancer cell line SW156 and mouse kidney cancer cell
line RAG were purchased from ATCC. Bladder cancer cell
line TSU-Pr-1 was obtained from Dr. Guang-Zhe Wu (Emory
University); lung cancer cell line 3LL, breast cancer cell line
BT-474, and human ovarian cancer cell line SK-OV-3 were
obtained from Dr. Lily Yang (Emory University). The primary
mBD1 null kidney cells and wild-type control cells were iso-
lated from the kidneys of 7 −14 day-old pups of mBD1-/- and
mBD1+ mice using a published protocol.49 Mouse kidney cell
colonies were selected using E-Cadherin expression as
a marker of kidney epithelial cells.50 All cells were maintained
in RPMI 1640 culture media with 10% fetal bovine serum
(FBS). For stable transfection and transduction selection, the
medium was supplemented with 800 μg-1000μg/ml of G418
(Invitrogen, Carlsbad, CA). Mycoplasma test for all cell lines
was performed every six months.
Plasmids
The hBD-1 coding sequence was removed from the commercial
hBD-1 expression vector pINCY (Incyte, Wilmington, DE) by
digesting with restriction enzymes EcoRI and NotI. The
sequence was then ligated into vectors of pcDNA 3.1(+) and
pLenti6.3 (Invitrogen, Carlsbad, CA). The sequence was ver-
ified through bidirectional sequencing with HITACHI 3100
Genetic Analyzer (Applied Biosystems). To express the hBD-
1 protein, cells were 60% to 70% confluent in a six-well plate
and incubated at 37°C overnight. Plasmids were then trans-
fected with Fugene 6 or Lipofectamine 2000 according to
the published protocols (Invitrogen, Carlsbad, CA). For
retro-/lentiviral gene transduction, the 2nd generation
Lentiviral packaging vectors, pCMV-ΔR8.91 and pMD.G
(Clonetech, Mountain View, CA) and the 3rd generation
Lentiviral package vectors (Invitrogen, Carlsbad, CA) were co-
transfected with a plasmid of pLenti6.3/hBD-1 into 293FT cells
(Invitrogen, Carlsbad, CA). Viral particles were harvested and
purified at day 4 or day 5 post transfection and used to infect
target cells as described in the published protocols.
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Tumorigenesis in mice
Mouse Beta Defensin1 (mBD1) knockout mice were originally
made in Dr. Julia Dorin laboratory (MRC Human Genetics
Unit, Western General Hospital, Scotland). The mBD1 knock-
out mice were generated by inserting a 1.1 Kb neo fragment
into mBD1 exon 2. Founder mice were then bred with C57BL/
6 mice.23 The genotype was verified by Southern blot using
genomic DNA extracted from the spleen. Mice were housed
under standard-care conditions in micro-isolators.
Experiments were performed using an IACUC approved pro-
tocol. Nickel sulfate was obtained from Dr. Jack Arbiser
(Emory University). Nickel sulfate was dissolved in DMEM
(Life Technologies, Grand Island, NY) to a final concentration
17mg/ml. According to Emory IACUC approved protocol,
100 µl of nickel sulfate solution was injected intramuscularly
into the left legs of 6-week-old male and female mBD1-/- mice
and control mice. The dilution vehicle was injected in the
right legs. The injection was performed only once; tumor
growth was monitored weekly for 1.5 years.
Tissue microarray and RT-PCR
The array membranes of mouse cell surface markers and
mouse common cytokines were purchased from SuperArray
Bioscience (Frederick, MD). Theprotocol was performed per
manufacturer instruction. The steps include RNA extraction
from combined tumor tissue, cDNA synthesis from the
extracted RNA, cRNA synthesis from the cDNA. Purified
cRNA was used to hybridize with the membranes. Data
were normalized by the gene GAPDH. The expression inten-
sity was quantified using ImageJ. Selected genes were vali-
dated by real-time RT-PCR using a BIO-RAD iCycler. Mouse
tumor cDNA was transcribed with TaqMan reverse transcript
reagents from Applied Biosystems (Branchburg, New Jersey,
USA). Samples were run in triplicate in qPCR using 2x Power
Sybr Green PCR master Mix from Applied Biosystems
(Branchburg, New Jersey, USA). Primer sequences are listed
in the supplemental table.
Immunohistochemistry
Tumor tissue from both mBD1-/- and wild-type mice were
fixed overnight at 4°C in 10% formalin and embedded in
paraffin. 5-µm sections were dewaxed by standard techniques.
A high-pressure Decloaking Chamber was used for tissue
antigens retrieval. Monoclonal mouse Anti-CD68 (Dako
Cytomation, Carpinteria, CA) was 1:100 diluted for staining.
DAKO LSAB/HRP kit was used for visualization.
Co-culture
TSU-PR1 cells were seeded in a 6-well plate and incubated at
37°C overnight. The plasmid pLenti6.3/hBD-1 and pLenti6.3/
LacZ were transfected into the cells using the standard proto-
col with Lipofectamine 2000 (Invitrogen, Carlsbad, CA). On
the same day of transfection, TSU-PR1 cells were seeded in
pre-soaked 0.45 µm co-culture inserts (Millipore, Billerica,
MA), incubated overnight, and then transferred into the
6-well plate that contained the cells previously transfected
with hBD-1 gene or LacZ gene as controls. The bottom of
each insert was sliced 2 x 1 cm openings at the edge with
a sterile scalpel for better interaction between two compart-
ments. Western blot analysis was performed with cell lysates
from both transfected and co-cultured TSU-PR1 cells at the
24, 48, and 72 h after co-incubation.
HPV16E6E7 production and infection
Retrovirus pLXSN16E6E7 was produced in PA317 packaging
cells (ATCC, Manassas, VA) by culturing the cells in RPMI
1640 with 10% FBS. The culture medium was harvested at
48–72 hours and filtered by a 0.45µC filter before infecting the
passage-2 mouse kidney cells. The cells were seeded in
a 6-well plate at 80% confluent overnight and then incubated
with 1 ml undiluted viral medium at 37ºC for 4–6 hours
followed by adding more culture medium to 4 ml per well.
Transduced cells were selected with 800µg/ml G418. The
mRNA and protein from transduced cells were analyzed by
RT-PCR and Western blot at the 7th day post-transduction.
Quantification of LacZ gene expression
Lentiviral-mediated gene transduction was quantified using
a LacZ reporter. TSU-PR1 cells were seeded at a density of
1 × 105 cells per well and transfected with pDNA3.1/hBD-1
and empty vector 48 hours prior to the infection with
Lenti6.3/LacZ recombinant virus. LacZ activity was deter-
mined from cell lysate at 24 h postviral infection by adding
ortho-Nitrophenyl-β-galactoside (ONPG) substrate. The
intensity of ortho-Nitrophenyl (ONP) in cell lysate was mea-
sured at 420/600 nm absorbance at different time points. The
600 nm absorbance was used to reflect cell density in each
well.28 The experiments were performed multiple times at
8–10 wells in each group.
Purification urine-derived hBD-1 peptide
Macro-Prep Carboxymethyl (CM) beads (Bio-Rad, Hercules,
CA) were equilibrated with 25 mM ammonium acetate (pH
6.8–7.2). Human urine or culture medium was collected and
centrifuged at 1000 rpm for 5 min to discard cells and pre-
cipitation. The equilibrated CM beads were added into urine
or cell medium at the ratio 1:10 and stirred overnight at 4°C.
Next day, the mixture was centrifuged at 1000 rpm for 3 min;
the supernatant was discarded, and the beads were washed
twice with 0.25 mM ammonium acetate (pH 8). To elute
hBD-1protein, two CM bead volumes of 5% acetic acid were
added and shaken at room temperature 5 to 10 min.8
Immunoprecipitation and western blot analysis
Whole-cell extracts were obtained by lysing cells with lysis
buffer containing 50 mmol/L Tris base, 5 mmol/L EGTA,
150 mmol/L NaCl, and 1% Triton X-100 (pH 7.4). One tablet
of protease inhibitor (Roche Diagnostics, South San Francisco,
CA) was dissolved in 7 mL of lysis buffer. Total protein
(30–50 μg/well) was loaded in 4–12% gradient NuPAGE
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MES SDS gel or 12.5% acid-urea page gel.8; the gel was then
transferred into Immun-Blot polyvinylidene difluoride mem-
brane. The anti-hBD-1 antibody was a gift from Dr. Thomas
Ganz (University of California, Los Angeles, CA). The other
primary antibodies were purchased from Cell Signaling
(pERK, HRAS, pAKT, pSP-6, and GAPDH) (Danvers, MA),
Calbiochem (HER2 Ab-3) (Billerica, MA), Santa Cruz
Biotechnology, Inc. (Neu C-18, pEGFR) (Dallas, TX), Sigma-
Aldrich (beta-Actin) (St. Louis, MO). Immunodetection was
completed by using the corresponding secondary horseradish
peroxidase (HRP)–conjugated antibodies. HRP activity was
detected using enhanced chemiluminescence from the ECL
Western blotting Analysis System (Thermo Scientific,
Rockford, IL). Data was normalized by β-Actin or GAPDH;
the intensity was quantified with ImageJ. For immunopreci-
pitation, 100–500 µg of BT474 total cell lysate was mixed with
50 µg urine-derived hBDF-1 peptides and incubated at 4ºC
overnight. Antibody conjugated Dynabeads Protein G (Life
technologies, Billerica, MA) was immobilized with 20 mM
dimethyl pimelimidate x 2HCl (DMP) and then added into
the protein mixture for 6 h at 4ºC. Before elution, the beads
were cross-linked with 5mM of BS3 (Thermo Scientific,
Rockford, IL) and washed three times with PBS with 0.1%
Tween-20 as described in a manufacturing protocol. Elution
proceeded with 0.1 mM citrate acid or SDS sample buffer. The
acid level in each sample that contained acetic acid or citrate
acid was adjusted with sodium hydroxide; the protein loading
dye was used as a chlorimetric pH indicator. Proteins were
analyzed in 4–12% of SDS-NuPAGE gel (Invitrogen,
Carlsbad, CA) and 10% of Tris/Glycine gel (BIO-RAD,
Hercules, CA).
Cell proliferation assay/cell viability assay
Bladder cancer cells TSU-Pr1were seeded in a 96-well plate at
40–50% confluent and incubated at 37°C overnight. The cul-
ture medium was changed daily with different concentrations
of urine-derived hDB-1 peptides and BSA controls. The pep-
tides were prepared in different pre-treatment conditions,
such as incubation at 95ºC, 5 min, 37ºC, 20 min and no
incubation. To lyse the cells, the culture plate was frozen at
−80°C and thawed at 37°C thrice. The dsDNA in each well
was quantified by adding 100 μL of aqueous Hoechst 33258 in
TNE buffer per well (Molecular Probes, Eugene, OR). The
fluorescence intensity was measured by a Microplate
Fluorescence Reader, BioTek FL600 (Winooski, VT). For cell
viability assay: 10 µl of WST-1 reagent (Roche, REF
11644807001, Mannheim, Germany) was added into each
well followed by incubating at 37ºC for 45 min to 1 h. The
plate was read at 450 nm and 690 nm. Data was analyzed by
subtracting the average of the media only wells from each the
differences between A450-A690 for treated cells and controls.
Statistical analysis
In this study, Western blots were repeated multiple times,
some more than 5 times. The films of each experiment were
exposed for different periods of time. To avoid detection
interference, we quantified the films that represented the
resulting signals within the linear range of detection. The
optical intensity of each band was captured multiple times
using ImageJ and then repeated with Adobe Photoshop for
comparable reference. The data were normalized for the back-
ground and internal controls. The quantification reflected
a ratio of each signal relative to the loading control and
housekeeping genes. Paired t-test was performed to compare
the means of two related groups; p-values were reported on
certain bar graphs that showed significant differences between
the two experimental groups.
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